Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Tobramycin: an overview.

× No keyword cloud information.

14 in total

1. Precautionary Practices of Respiratory Therapists and Other Health-Care Practitioners Who Administer Aerosolized Medications.

Authors: Rebecca J Tsai; James M Boiano; Andrea L Steege; Marie H Sweeney
Journal: Respir Care Date: 2015-07-07 Impact factor: 2.258

2. Rapid, reproducible enzyme immunoassay for tobramycin.

Authors: E L Francke; S Srinivasan; P Labthavikul; H C Neu
Journal: J Clin Microbiol Date: 1981-01 Impact factor: 5.948

Review 3. Antibiotic pharmacokinetics in cystic fibrosis. Differences and clinical significance.

Authors: R de Groot; A L Smith
Journal: Clin Pharmacokinet Date: 1987-10 Impact factor: 6.447

4. In vitro models to detect in vivo bile acid changes induced by antibiotics.

Authors: Nina Zhang; Jingxuan Wang; Wouter Bakker; Weijia Zheng; Marta Baccaro; Aishwarya Murali; Bennard van Ravenzwaay; Ivonne M C M Rietjens
Journal: Arch Toxicol Date: 2022-09-08 Impact factor: 6.168

5. Comparative nephrotoxicity of gentamicin and tobramycin in rats.

Authors: D N Gilbert; C Plamp; P Starr; W M Bennet; D C Houghton; G Porter
Journal: Antimicrob Agents Chemother Date: 1978-01 Impact factor: 5.191

6. Activity of 5-episisomicin compared with that of other aminoglycosides.

Authors: K P Fu; H C Neu
Journal: Antimicrob Agents Chemother Date: 1978-08 Impact factor: 5.191

Review 7. Selective decontamination of the digestive tract: the mechanism of action is control of gut overgrowth.

Authors: Luciano Silvestri; Miguel A de la Cal; Hendrick K F van Saene
Journal: Intensive Care Med Date: 2012-09-22 Impact factor: 17.440

8. Imipenem therapy of Pseudomonas aeruginosa and other serious bacterial infections.

Authors: D J Winston; M A McGrattan; R W Busuttil
Journal: Antimicrob Agents Chemother Date: 1984-11 Impact factor: 5.191

9. Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial.

Authors: Eitan Kerem; Michael W Konstan; Kris De Boeck; Frank J Accurso; Isabelle Sermet-Gaudelus; Michael Wilschanski; J Stuart Elborn; Paola Melotti; Inez Bronsveld; Isabelle Fajac; Anne Malfroot; Daniel B Rosenbluth; Patricia A Walker; Susanna A McColley; Christiane Knoop; Serena Quattrucci; Ernst Rietschel; Pamela L Zeitlin; Jay Barth; Gary L Elfring; Ellen M Welch; Arthur Branstrom; Robert J Spiegel; Stuart W Peltz; Temitayo Ajayi; Steven M Rowe
Journal: Lancet Respir Med Date: 2014-05-15 Impact factor: 30.700

10. Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: The international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF).

Authors: M W Konstan; D R VanDevanter; S M Rowe; M Wilschanski; E Kerem; I Sermet-Gaudelus; E DiMango; P Melotti; J McIntosh; K De Boeck
Journal: J Cyst Fibros Date: 2020-01-23 Impact factor: 5.527